CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vicuron Pharmaceuticals, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vicuron Pharmaceuticals, Inc.
455 South Gulph Road
Phone: (610) 205-2300p:610 205-2300 King of Prussia, PA  19406  United States

This company was Merged or Acquired on 9/14/2005.
This company ceased filing statements with the SEC on 9/14/2005.
This is a Subsidiary, click here for the Parent Company

Business Summary
Vicuron Pharmaceuticals, Inc. a biopharmaceutical company focuses on seeking to develop antibiotics and antifungals with characteristics, such as greater potency, improved effectiveness against difficult to treat strains and reduced toxicity. The Company's lead anti-fungal product candidate, Anidulafungin, is intended for the intravenous (IV) treatment of fungal infections. Its lead antibiotic product candidate, Dalbavancin, is a second-generation lipoglycopeptide antibiotic intended for the treatment of serious infections, particularly those caused by Staphylococci. Vicuron's third product candidate, Ramoplanin, is an oral non-absorbable form of antibiotic called lipopeptide. The Company's fourth product candidate, VIC-Acne, is an antibiotic that the Company is developing as a topical cream. In December 2004, the Company submitted a new drug application (NDA) for dalbavancin, an antibiotic for the treatment of complicated skin and soft-tissue infections (cSSTIs).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/200512/31/2004YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director George F.Horner, III 60 1/1/1996 1/1/1996
Chief Financial Officer, Executive Vice President Dov A.Goldstein, M.D. 37 8/1/2003
Executive Vice President, Chief Medical Officer David S.Krause, M.D 56 1/1/2005 1/1/2003
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Biosearch Manufacturing
MICU
Vicuron Pharmaceuticals, Inc.

General Information
Number of Employees: 216 (As of 12/31/2004)
Outstanding Shares: 61,172,779 (As of 9/15/2005)
Shareholders: 70
Stock Exchange: NASD
Federal Tax Id: 043278032
Email Address: info@versicor.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023